Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients

Hang Zhang, Chang Pan, Juan Zhang, Lin-Lin Zhu, Kai Huang, Yun Zhong, Zuo-Ying Hu
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China

Abstract

Background: Atrial fibrillation (AF) is the most frequent tachyarrhythmia in patients with a permanent pacemaker. Angiotensin II receptor antagonists have a protective effect against the occurrence of AF in patients with heart diseases. This study aimed to assess the effectiveness of olmesartan in the prevention of new-onset AF and AF burden in atrioventricular block (AVB) patients with dual-chamber (DDD) pacemaker implantation.

Methods: This was a single-center, prospective, randomized, single-blind, controlled clinical study. A total of 116 AVB patients, who received DDD pacemakers implantation with the percentage of ventricular pacing (VP%) ≥40% from April 22, 2011 to December 24, 2012, were prospectively randomized to olmesartan group (20 mg per day; n = 57) or control group (n = 59). Patients were followed up using pacemaker programming, 12-lead electrocardiography in the intrinsic sinus rhythm, laboratory examinations, and transthoracic echocardiography at 24 months. Atrial high rate events (AHREs) were defined as 180 beats/min over a minimum of 5 min. AF burden was calculated by the number of hours with AHREs divided by the number of measurement hours.

Results: Ten (17.5%) patients in the olmesartan group and 24 patients (40.7%) in the control group occurred new-onset AF, and the difference between two groups was statistically significant (P = 0.04). AF burden was lower in olmesartan group than that in control group (8.02 ± 3.10% vs. 13.66 ± 6.14%, P = 0.04). There were no significant differences in mean days to the first occurrence of AHREs and mean cumulative numbers of AHREs between two groups (P = 0.39 and P = 0.42, respectively). Moreover, olmesartan group had smaller values of maximal P-wave durations and P-wave dispersion (PD) after 24 months follow-up compared with the control group (109.5 ± 7.4 ms vs. 113.4 ± 7.1 ms, P = 0.00; and 40.6 ± 4.5 ms vs. 43.3 ± 4.4 ms, P = 0.02, respectively). Left ventricular end-diastolic diameter and left ventricular ejection fraction were not significantly different between two groups (both P > 0.05).

Conclusion: This study suggested that 24-month of olmesartan therapy could reduce new-onset AF and AF burden in patients with DDD pacemakers.

Clinical Trial Registration: ChiCTR-TRC-12004443; http://www.chictrdb.org.

Key words: Angiotensin II Receptor Antagonist; Atrial Fibrillation; Olmesartan; Pacemaker; Ventricular Pacing

INTRODUCTION

Atrial fibrillation (AF) is the most frequent tachyarrhythmia in patients with a permanent pacemaker, occurring in up to 88.6% of patients with prior history of AF and 53.8% of patients without prior AF history at 24 months postimplant.[1] Atrial high rate episodes (AHREs) may be brief, infrequent, and asymptomatic, and may be detected before clinical arrhythmia is apparent. These subclinical device-detected AHREs are associated with an increased stroke risk, similar to, but to a lesser degree than, clinically apparent AF detected by routine methods.[2] The only therapeutic strategy that has been demonstrated to be effective in reducing the occurrence of AF in these patients is minimizing ventricular pacing (VP).[3] However, minimal VP algorithms are not suitable for patients with advanced atrioventricular block (AVB). Recently, several...
clinical and experimental studies have reported a protective effect of the angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists against the occurrence of AF in patients with heart diseases (e.g., hypertension, heart failure, cardiac hypertrophy, and so on). However, these results have not been consistently replicated in the cohort of pacemaker patients.

In the present study, we examined patients without previous history of AF, who were implanted dual-chamber (DDD) pacemakers, to assess the effectiveness of olmesartan in the prevention of new-onset AF and AF burden in AVB patients with high VP% (≥40%).

**Methods**

**Patients selection**

This was a single-center, prospective, randomized, single-blinded, controlled clinical study. Patients with the age of ≥40 years and <80 years, who had AVB and met the indication for a permanent dual-chamber cardiac pacing, were consecutively recruited from April 22, 2011 to December 24, 2012, in Nanjing First Hospital. After a 1-week run-in period, the patients with the VP% ≥40% were included in the study.

Patients were excluded if they had received an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACEI) in the past month or had received therapy with antiarrhythmic agents (sodium or potassium channel blockers within 4 half-lives; amiodarone within the past 3 months). Other exclusion criteria included heart failure with reduced ejection fraction, proteinuria, serum potassium level ≥5 mmol/L, known bilateral renal artery stenosis, serum creatinine level ≥30 mg/L, established paroxysmal AF (documentation of AF in at least one electrocardiography [ECG] recorded before randomization), left atrial (LA) diameter ≥6 cm, hyperthyroidism, heart surgery within 3 months, and participation in another clinical trial within the past 30 days.

The study was approved by the Ethical Committee of Nanjing First Hospital and was conducted according to the Declaration of Helsinki. A written informed consent was obtained from the patients before participation.

**Study design**

The trial was designed to detect a 50% relative reduction in the risk of AF from a rate of 50% in the control group to 25% in the treatment group. Using a two-tailed test, a type I error of 0.05, a power of 90%, and a 10% drop-out rate to fulfill the criteria of intention-to-treat analysis, we calculated that we need 120 patients, 60 in each group, to show the superiority of olmesartan over placebo.

Seven days after implantation of the pacemaker, the patients with the VP% ≥40% were randomized to olmesartan group (20 mg olmesartan per day) or control group (no olmesartan) at a 1:1 ratio according to the computer generated random number by one certain researcher. The patients were nonblinded in the study. In case of suspected intolerance of the study medication, study medication was terminated. Each patient was followed up for a period of 24 months after enrollment according to the schedule.

Follow-up visits were scheduled at 1 month, 6 months, 12 months, 18 months, and 24 months. Patients were asked to record actual medication, physical examination, arterial blood pressure, 12-lead ECG in the intrinsic sinus rhythm, sodium, potassium, creatinine, transthoracic echocardiography, and pacemaker programming. All the physicians, pacemaker interrogators, and the data recorders involved in follow-up did not know the grouping. Two investigators performed the analyses for each participant separately using the same protocol. We used the mean values of the parameters from the two investigators for statistics. The study design is illustrated in Figure 1.

**Pacemaker programming**

All the pacemakers Relia RED(R), Sensia SED(R), Adapt DDD(R) (Medtronic Inc., Minnesota, USA) and Identity™ 5286, Victory™ 5816, and 5826 (St. Jude Medical, Minnesota, USA) implanted in this study have high sensitivity and specificity for the detection of AF or AHREs. The algorithm was recommended to optimize AF detection and minimize VP. The detection threshold for AHRE was set to be 180 beats/min over a minimum of 5 min. It was essential that the devices were programmed appropriately to avoid far-field R-wave oversensing and atrial undersensing to ensure a high sensitivity and specificity for AF detection. Validation of appropriate detection of AHRE or AF was also carried out by looking at atrial electrograms to exclude false-positive detection. While the pacemakers offer automatic atrial override in response to high intrinsic atrial rates, this feature was not used during the study to permit assessment of a simpler approach to preventing AF.

VP% and atrial pacing (AP%) were recorded. The new-onset AF, the days to the first occurrence of documented AHRE, cumulative numbers of AHREs in the follow-up were also recorded. The AF burden was calculated by the number of hours with AHREs divided by the number of measurement hours.

**P-wave dispersion**

P waves on all derivations were synchronously recorded on standard 12-lead surface ECGs at 50 mm/s paper speed and 20 mm/mV standardization in the intrinsic rhythm. The onset of the P-wave was defined as the point of first visible upward slope from baseline for positive waveforms and as the point of the first downward slope from baseline for negative waveforms. The return to the baseline was considered as the end of the P-wave. The average P-wave of three consecutive beats from each lead was determined. Maximum P-wave duration (Pmax) was defined as the longest P-wave duration, and minimum P-wave duration (Pmin) was defined as the shortest P-wave duration in all derivations. P-wave dispersion (PD) was defined as the difference between Pmax and Pmin.
Echocardiographic examination

All echocardiographic examinations were performed with GE Vivid 7 (GE Healthcare, Wisconsin, USA) using cardiac ultrasound scanner 2.0–3.5 MHz transducers. One lead ECG was recorded continuously. All the patients were in sinus rhythm. LA end-systolic diameters, left ventricular end-systolic, and end-diastolic dimensions were measured from M mode in the parasternal long axis views according to the American Society of Echocardiography’s guideline. Ejection fractions were measured according to the Simpson method.

Study endpoints

The primary endpoint was the presence of new-onset AF confirmed by pacemaker programming during 24-month follow-up. Secondary end-points of the study were AF burden, PD, and echocardiographic findings for LA size.

Statistical analysis

Data are expressed as mean ± standard deviation (SD) or percent. Student’s t-test was used for comparing continuous variables. Differences in portions were judged by Chi-square test. The two-tailed paired t-test was used to compare the data before and after pacemaker implanting. The significance of the different variables in the prediction of new-onset AF was assessed using univariable analysis, and then significant factors were inserted in a multivariable logistic regression analysis. Relative risks were estimated using exposure odds ratios (ORs) from cross-tabulation. A \( P < 0.05 \) was considered to be statistically significant. Analyses were performed using the SPSS version 19.0 (SPSS Inc., Chicago, IL, USA).

Results

A total of 116 patients (68 males and 48 females) were enrolled in this study, with the mean age of 65.1 ± 10.5 years (range: 43–80 years); and there were 57 patients in olmesartan group and 59 patients in control group. No statistically significant difference was observed between the two groups when basic clinical parameters of the patients were compared [Table 1].

The AP% and VP% were not significantly different between two groups after 24-month follow-up (\( P = 0.18 \) and \( P = 0.89 \), respectively). Among the 116 patients, 34 patients (23 males and 11 females, mean age: 70.0 ± 9.0 years, range: 54–79 years) developed new atrial tachyarrhythmia during 24-month follow-up. The numbers of patients occurring new-onset AF were 3, 6, 7, 4, and 4 in the control group and 2, 3, 2, 1, and 2 in the olmesartan group at 1 month, 6 months, 12 months, 18 months, and 24 months, respectively and the difference between two groups was statistically significant (\( P = 0.04 \)). AF burden in the olmesartan group was lower than that in the control group after 24 months follow-up (8.02 ± 3.10 vs. 13.66 ± 6.14, \( P = 0.04 \)) [Figure 2].

Intracardiac electrograms of every recorded AHRE were assessed and classified (AF vs. no AF) by two experienced cardiologists who were blinded to the groups. During 24 months follow-up, 1239 AHRE were recorded and classified in 34 patients. Among 1239 episodes, 1170 episodes (94.4%) were true AHREs. Our results were based on the true AHREs. After 24 months follow-up, there was no significant difference in days to the first occurrence of AHREs between two group, which was 293.8 ± 197.5 days.
in the olmesartan group and 286.7 ± 191.7 days in the control group ($P = 0.89$); there was also no significant difference in cumulative numbers of AHREs between the two groups ($P = 0.42$) [Table 2].

Table 3 shows the hemodynamic, ECG, and echocardiographic parameters between two groups before and 24 months after treatment. According to the parameters before and 24 months after treatment, blood pressure was reduced from $132.2 ± 14.4/81.1 ± 8.8$ mmHg ($1\text{mmHg}=0.133\text{kPa}$) to $128.3 ± 20.1/75.1 ± 6.3$ mmHg in the olmesartan group, while stayed at $130.3 ± 15.1/80.2 ± 10.4$ mmHg to $128.5 ± 11.1/78.2 ± 10.6$ mmHg in the control group. The parameters of $P_{\text{max}}$ and $PD$ changed significantly before and 24 months after treatment in control group ($104.2 ± 7.3\text{ms}$ vs. $113.4 ± 7.1\text{ms}$, $P = 0.00$; and $38.5 ± 3.6\text{ms}$ vs. $43.3 ± 4.4\text{ms}$, $P = 0.00$, respectively). The parameter of $PD$ showed no remarkable change before and 24 months after treatment in the olmesartan group ($38.9 ± 3.4\text{ms}$ vs. $40.6 ± 4.5\text{ms}$, $P = 0.14$). LA end-systolic diameter at 24-month follow-up tended to be smaller than that before treatment in the olmesartan group ($40.8 ± 4.3\text{mm}$ vs. $41.5 ± 5.1\text{mm}$); however, the difference failed to achieve statistical significance ($P = 0.08$). LA end-systolic diameter also had no remarkable change before and 24 months after treatment in the control group ($P = 0.06$).

According to the parameters between two groups, olmesartan group had smaller values of $P_{\text{max}}$ and $PD$ after 24 months follow-up compared to the control group ($109.5 ± 7.4\text{ms}$ vs. $113.4 ± 7.1\text{ms}$, $P = 0.00$; $40.6 ± 4.5\text{ms}$ vs. $43.3 ± 4.4\text{ms}$, $P = 0.02$, respectively). However, the values of LA end-systolic diameter and left ventricular ejection fraction (LVEF) had no changes between two groups before treatment and after 24 months follow-up.

Multivariable logistic regression analyses showed that the predicted factors for new-onset AF were male ($OR: 3.865$, $95\%\text{CI}: 1.342–11.127$; $P = 0.01$), LA diameter ($OR: 1.146$, $95\%\text{CI}: 1.050–1.250$; $P = 0.00$), and olmesartan recipe ($OR: 0.327$, $95\%\text{CI}: 0.109–0.978$; $P = 0.04$).

**Discussion**

This study showed that the use of 20 mg olmesartan per day reduced the prevalence of new-onset AF and AF burden in

---

**Table 1: Baseline characteristics of all patients in this study**

| Characteristics          | Olmesartan group ($n = 57$) | Control group ($n = 59$) | $P$  |
|--------------------------|------------------------------|--------------------------|------|
| Age (years), mean ± SD   | 64.8 ± 10.9                  | 65.3 ± 10.3              | 0.89 |
| Male, n (%)              | 35 (61.4)                    | 33 (55.9)                | 0.58 |
| Smoking, n (%)           | 17 (29.8)                    | 15 (25.4)                | 0.68 |
| Diabetes mellitus, n (%) | 15 (26.3)                    | 13 (22.0)                | 0.67 |
| Coronary artery disease, n (%) | 14 (24.5)        | 10 (16.9)                | 0.69 |
| Hypertension, n (%)      | 25 (43.8)                    | 24 (40.7)                | 0.85 |
| β-blocker                | 7 (12.3)                     | 8 (13.6)                 | 0.87 |
| Dihydropyridine calcium antagonist | 20 (35.1)     | 21 (35.6)                | 0.96 |
| Diltiazem                 | 2 (3.5)                      | 2 (3.3)                  | 1.00 |
| Verapamil                 | 1 (1.8)                      | 0                        | 0.49 |
| Diuretics                | 10 (17.5)                    | 8 (13.6)                 | 0.61 |
| Nitrate                  | 13 (22.8)                    | 12 (20.3)                | 0.82 |
| Statins                  | 12 (21.1)                    | 12 (20.3)                | 0.92 |
| Aspirin                  | 17 (29.8)                    | 18 (30.5)                | 0.94 |
| Oral anticoagulants      | 1 (1.8)                      | 0                        | 0.49 |

SD: Standard deviation.

**Table 2: Pacemaker parameters after 24-month follow-up in olmesartan and control groups in this study**

| Parameters                          | Olmesartan group ($n = 57$) | Control group ($n = 59$) | Statistical values | $P$  |
|-------------------------------------|-----------------------------|--------------------------|-------------------|------|
| AP (%)                              | 12.6 ± 7.3                  | 13.9 ± 5.2               | −1.10*            | 0.18 |
| VP (%)                              | 71.6 ± 22.0                 | 72.2 ± 18.7              | −0.09*            | 0.89 |
| Patients occurred new-onset AF      | 10 (17.5)                   | 24 (40.7)                | 5.19*             | 0.04 |
| Days to the first occurrence of AHREs (days) | 293.8 ± 197.5   | 286.7 ± 191.7            | −0.14*            | 0.89 |
| Cumulative numbers of AHREs (episodes/patient) | 22.8 ± 19.2      | 28.4 ± 18.4              | 0.13*             | 0.42 |
| Duration of AHRE episodes (h/day)    | 1.93 ± 0.75                 | 3.29 ± 1.45              | 2.78*             | 0.04 |
| AF burden (%)                       | 8.02 ± 3.10                 | 13.66 ± 6.14             | −                 | 0.04 |

Data are shown as mean ± SD or n (%). *t value; †χ² value. AF: Atrial fibrillation; AP: Atrial pacing; VP: Ventricular pacing; AHREs: Atrial high rate episodes; SD: Standard deviation; −: Not applicable.
Our data suggested the beneficial effects of 24 months of olmesartan therapy for the reduction of new-onset AF and AF burden were similar between two groups. Previous studies have suggested that ACEIs or ARBs prevented the development of AF in patients with LV dysfunction.[4,5,12] As well, the Losartan Intervention For Endpoint reduction in hypertension study demonstrated losartan-based therapy significantly reduced new-onset AF by 33% compared to atenolol-based therapy, with similar blood pressure reduction.[13] The target for therapy with the renin-angiotensin-aldosterone system inhibitors was to prevent LA stretch and dilatation secondary to left ventricular dyssynchrony and dysfunction caused by long-term right VP.[14] In particular, olmesartan can effectively inhibit pressure overload-induced cardiac hypertrophy even in angiotensinogen-knockout mice lacking endogenous angiotensin II.[15] However, angiotensin II-antagonist in paroxysmal AF trial failed to prove that 1 year of olmesartan therapy reduced the number of AF episodes in patients with documented paroxysmal AF without structural heart disease.[16]

P-wave duration by signal-averaged ECG has been shown to be useful for identifying patients at risk for AF. PD appeared to be related to the LA size and function.[17] Demir et al.[18] reported that in patients with DDD pacemakers, increased LA dimension, Pmax value of 120 ms, and PD value of 40 ms was associated with significantly increased risk of persistent AF. Our study observed that pacing prolonged the values of Pmax and PD. Therapy of 20 mg olmesartan per day for 24 months significantly reduced adverse electrical remodeling caused by pacing. It is one of the possible mechanisms of olmesartan reducing AF in pacemaker patients. However, there was a minimal decrease in the LA size at 24-month follow-up in the olmesartan group, which was parallel with a minimal increase in the size in the control group, without statistical significance. Maybe a longer follow-up or larger study samples can reveal the difference of structure remodeling among patients with pacemaker implantation.

Our study had some limitations that should be taken into consideration. First, this was only a single-center and nonblinded study. Second, six different pacemaker models

Table 3: Comparison of parameters between olmesartan and control groups before and 24 months after treatment

| Variables                  | Olmesartan group (n = 57) | Control group (n = 59) | t   | P     |
|----------------------------|---------------------------|------------------------|-----|-------|
| Heart rate (beats/min)     |                           |                        |     |       |
| Before                     | 60.6 ± 12.6               | 57.9 ± 13.6            | 1.120 | 0.27  |
| At 24-month                | 66.0 ± 5.2                | 68.5 ± 6.5             | −2.230 | 0.06  |
| t                          | −3.46                     | −7.02                  |     |       |
| P                          | 0.00                      | 0.00                   |     |       |
| Systolic BP (mmHg)         |                           |                        |     |       |
| Before                     | 132.2 ± 14.4              | 130.3 ± 15.1           | 2.210 | 0.16  |
| At 24-month                | 128.3 ± 20.1              | 128.5 ± 11.1           | 2.090 | 0.71  |
| t                          | 3.57                      | 1.83                   |     |       |
| P                          | 0.04                      | 0.52                   |     |       |
| Diastolic BP (mmHg)        |                           |                        |     |       |
| Before                     | 81.1 ± 8.8                | 80.2 ± 10.4            | 1.090 | 0.59  |
| At 24-month                | 75.1 ± 6.3                | 78.2 ± 10.6            | 1.910 | 0.05  |
| t                          | 3.82                      | 1.62                   |     |       |
| P                          | 0.03                      | 0.78                   |     |       |
| SCr (µmol/L)               |                           |                        |     |       |
| Before                     | 96.4 ± 8.7                | 94.3 ± 12.1            | 1.410 | 0.28  |
| At 24-month                | 94.7 ± 7.6                | 95.7 ± 8.1             | 1.120 | 0.61  |
| t                          | 2.05                      | 1.57                   |     |       |
| P                          | 0.32                      | 0.56                   |     |       |
| Pmax (ms)                  |                           |                        |     |       |
| Before                     | 101.9 ± 7.6               | 104.2 ± 7.3            | −1.602 | 0.11  |
| At 24-month                | 109.5 ± 7.4               | 113.4 ± 7.1            | −2.886 | 0.00  |
| t                          | −7.32                     | −7.34                  |     |       |
| P                          | 0.00                      | 0.00                   |     |       |
| PD (ms)                    |                           |                        |     |       |
| Before                     | 38.9 ± 3.4                | 38.5 ± 3.6             | 0.624 | 0.54  |
| At 24-month                | 40.6 ± 4.5                | 43.3 ± 4.4             | −3.208 | 0.02  |
| t                          | −1.55                     | −3.45                  |     |       |
| P                          | 0.14                      | 0.00                   |     |       |
| LA end-systolic diameter (mm) |                         |                        |     |       |
| Before                     | 41.5 ± 5.1                | 42.0 ± 6.0             | −0.910 | 0.37  |
| At 24-month                | 40.8 ± 4.3                | 43.6 ± 5.9             | −2.919 | 0.06  |
| t                          | 0.51                      | −0.47                  |     |       |
| P                          | 0.08                      | 0.06                   |     |       |
| LVEF (%)                   |                           |                        |     |       |
| Before                     | 58.7 ± 6.9                | 60.6 ± 6.9             | −1.372 | 0.17  |
| At 24-month                | 59.2 ± 7.1                | 59.1 ± 7.1             | −1.997 | 0.57  |
| t                          | 1.71                      | 2.58                   |     |       |
| P                          | 0.12                      | 0.05                   |     |       |

Data are shown as mean ± SD. BP: Blood pressure; SCr: Serum creatinine; Pmax: Maximal P-wave duration; PD: P-wave dispersion; LVEF: Left ventricular ejection fraction; SD: Standard deviation; LA: Left atrial.
from two different companies were used in the study. Even there were no significant differences in device mix between the two study groups, the possibility of the different detection algorithms affecting the results could not be ruled out.

In conclusion, this study proved that 24-month of olmesartan therapy could reduce new-onset AF and AF burden in patients with DDD pacemakers.

Financial support and sponsorship
This work was supported by grants from Nanjing City Special Program of Medical Science (No. YKK12089) and Jiangsu Provincial Special Program of Medical Science (No. BL2013001).

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Orlov MV, Ghali JK, Araghi-Niknam M, Sherfesee L, Sahr D, Hettrick DA. Atrial High Rate Trial Investigators. Asymptomatic atrial fibrillation in pacemaker recipients: Incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol 2007;30:404-11. doi:10.1111/j.1540-8159.2007.00682.x.

2. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, et al. Device-detected atrial fibrillation and risk for stroke: An analysis of ~10,000 patients from the SOS AF project (Stroke prevention Strategies on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35:508-16. doi: 10.1093/eurheartj/ehu291.

3. Ricci RP, Botto GL, Bénézet JM, Nielsen JC, De Roy L, Piot O, et al. Association between ventricular pacing and persistent atrial fibrillation in patients indicated to elective pacemaker replacement: Results of the Prefer for Elective Replacement MVP (PreFER MVP) randomized study. Heart Rhythm 2015;12:2239-46. doi: 10.1016/j.hrthm.2015.06.041.

4. Savelieva I, Kourouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary prevention. Europace 2011;13:308-28. doi: 10.1093/europace/eur002.

5. Savelieva I, Kourouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary prevention. Europace 2011;13:610-25. doi: 10.1093/europace/eur023.

6. Sparks PB, Mond HG, Vohra JK, Yapanis AG, Grigg LE, Kalman JM. Mechanical remodeling of the left atrium after loss of atrioventricular synchrony. A long-term study in humans. Circulation 1999;100:1714-21. doi: http://dx.doi.org/10.1161/01.CIR.100.16.1714.

7. Guyomar Y, Thomas O, Marquáé C, Jarwe M, Klug D, Kacet S, et al. Mechanisms of onset of atrial fibrillation: A multicenter, prospective, pacemaker-based study. Pacing Clin Electrophysiol 2003;26:1336-41.

8. Mittal S, Stein K, Gilliam FR 3rd, Kraus SM, Meyer TE, Christian SA. Frequency, duration, and predictors of newly-diagnosed atrial fibrillation following dual-chamber pacemaker implantation in patients without a previous history of atrial fibrillation. Am J Cardiol 2008;102:450-3. doi:10.1016/j.amjcard.2008.03.080.

9. Radelic J, Pavlovic N, Manola S, Delic-Brkljacic D, Pintaric H, Petroc D. Incidence and predictors of asymptomatic atrial fibrillation in patients older than 70 years with complete atrioventricular block and dual chamber pacemaker implantation. Croat Med J 2011;52:61-7. doi: 10.3325/cmj.2011.52.61.

10. Said S, Cooper CJ, Alkhateeb H, Gosavi S, Dwivedi A, Ouante E, et al. Incidence of new-onset atrial fibrillation in patients with permanent pacemakers and the relation to the pacing mode. Med Sci Monit 2014;20:628-73. doi: 10.12659/MSM.890052.

11. Williams SG, Connelly DT, Jackson M, Bennett A, Albouaini K, Todd DM. Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation during dual chamber pacemaker implantation? Europace 2005;7:554-9. doi: 10.1016/j.eur.2005.06.003.

12. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr., Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:2305-7. doi: 10.1016/j.jacc.2014.03.022.

13. Wachtell K, Lehto M, Gerds T, Olsen MH, Hormestam B, Dahlbo F. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005;45:712-9. doi: 10.1016/j.jacc.2004.10.068.

14. Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials. Int J Cardiol 2013;165:17-24. doi:10.1016/j.ijcard.2012.02.009.

15. Li L, Zhou N, Gong H, Wu J, Lin L, Komuro I, et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res 2013;36:1299-306. doi: 10.1007/s10992-013-1657-7.

16. Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012;5:43-51. doi: 10.1161/CIRCEP.111.965178.

17. Dogan A, Kahraman H, Ozurtok M, Avsar A. P wave dispersion and left atrial appendage function for predicting recurrence after conversion of atrial fibrillation and relation of P wave dispersion to appendage function. Echocardiography 2004;21:523-30. doi: 10.1111/j.1040-724X.2004.01333.x.

18. Demir AD, Soylu M, Ozdemir O, Balbay Y, Topaloglu S, Sasmaz A, et al. Determinants of persistent atrial fibrillation in patients with DDD pacemaker implantation. Pacing Clin Electrophysiol 2003;26:719-24. doi:10.1046/j.1460-9592.2003.00122.x.